Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIIb, Randomized, Open-Label, Parallel Group, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Two Dosing Regimens of Ropeginterferon Alfa-2b-njft (P1101) in Adult Patients With Polycythemia Vera (PV)

NCT05481151 is registered in ClinicalTrials.gov with PharmaEssentia as lead sponsor.

NCT NCT05481151
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05481151 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIIb, Randomized, Open-Label, Parallel Group, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Two Dosing Regimens of Ropeginterferon Alfa-2b-njft (P1101) in Adult Patients With Polycythemia Vera (PV)
Lead sponsor
PharmaEssentia
Phase
Phase 3
Overall status
Active, not recruiting
Start date
October 26, 2022
Completion date
July 31, 2027
Enrollment
111 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

polycythemia vera